Phase 4 N=38 Treatments for Psychogenic Nonepileptic Seizures (NES)
Convulsion, Non-Epileptic · Conversion Disorder · Depression
Primary: Number of Nonepileptic Seizures (NES) — 5.0; 6.0; 3.0; 6.0 seizures — p=0.29
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Treating Non-epileptic Seizures Using Magnetic Brain Stimulation
Nonepileptic Seizures
Primary: Number of Weekly Psychogenic Non-epileptic Seizure-events — 6.9; 5.3 events
N/A N=30 Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
N/A N=29 Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures
Convulsion, Non-Epileptic
Primary: Completion Rate of Auricular Acupuncture in Patients With NES — 15 Participants
N/A N=60 Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures
Psychogenic Non-epileptic Seizures, Motivational Interviewing
Primary: Adherence — 9; 17 Participants — p=0.015
N/A N=20 EEG Cap for Identification of Non-Convulsive Status Epilepticus
Nonconvulsive Status Epilepticus · Subclinical Seizure · Altered Mental Status
Primary: Time Difference Between EEG Cap and Standard EEG Results Reporting — 103.4 minutes — p=0.0005
Phase 1 N=13 Nonconvulsive Electrotherapy: a Proof-of-concept Trial
Depressive Disorder · Bipolar Disorder · Schizoaffective Disorder
Primary: Change in Score on the 17-item Hamilton Depression Rating Scale — -11.6 units on a scale — p=0.001
Phase 3 N=893 Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications
Status Epilepticus
Primary: Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given — 329; 282 participants — p=<0.001
Phase 2 N=74 Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures
Nonconvulsive Seizures
Primary: Percentage of Subjects Who Experience no Nonconvulsive Seizures (NCS) for 24 Hours Following Treatment With LCM vs. fPHT, as Measured by Continuous…
N/A N=40 Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?
Chest Pain Atypical Syndrome
Primary: Mean Change in Esophageal Length With Acid — -0.40; -0.39 centimeters
N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
N/A N=3 Cardioneuroablation for Neurocardiogenic Syncope
Neurocardiogenic Syncope · Vasovagal Syncope
Primary: Syncope Recurrence Rate
N/A N=31 Seizure Detection and Automatic Magnet Mode Performance Study
Epilepsy
Primary: Summary of Seizures Reported by Investigators and Triple Review — 87; 124; 211; 82 Seizures
Phase 4 N=103 Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
Epilepsy, Idiopathic Generalized
Primary: Time to First Seizure — 169; 178 Days
N/A N=47 Auricular Neurostimulation for Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome · Abdominal Migraine
Primary: Rhodes Index of Nausea, Vomiting & Retching (INVR) — 3.25; 5.80; 10.43; 0.75 score on a scale
Phase 2 N=129 The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Syncope, Vasovagal
Primary: Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test — 32; 27; 33; 35 Participants — p=0.521
Phase 3 N=251 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
N/A N=303 Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study
Neonatal Seizures
Primary: WIDEA Neurodevelopmental Outcome Score — 149.04; 162.46; 148.80; 151.89 score on a scale
Phase 2 N=50 External Trigeminal Nerve Stimulation for Epilepsy
Epilepsy · Seizure Disorders
Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants
N/A N=44 Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims
Cardiac Arrest
Primary: Percentage of Seizure-positive and Seizure-negative That Were Correctly Classified by the SEDline in All Evaluated Cases — 100 percentage of seizures
Phase 3 N=56 Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder
PostTraumatic Stress Disorder
Primary: Level of Interleukin-6 (IL6) — 0.88; 0.84; 1.77; 2.11 pg/ml
N/A N=12 Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor
Dystonia · Tremor
Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale
Phase 2 N=147 A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
Phase 3 N=219 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
Generalized Tonic Clonic Seizures
Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…
N/A N=80 Premenstrual Dysphoric Disorder and Antiepileptic Drugs
Epilepsy
Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants
Phase 2 N=24 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Epileptic Encephalopathy · Continuous Spike and Wave During Sleep
Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326
Phase 2 N=6 VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa
Status Epilepticus, Electrographic · Coma
Primary: Primary Pharmacologic Outcome - Absorption — 6; 0 Participants
Phase 2 N=59 Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Myotonia · Non-Dystrophic Myotonia
Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001
N/A N=20 The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
Major Depression
Primary: Wechsler Memory Scale-III (WMS-III) Auditory Delayed Index
N/A N=60 Neocortical Epilepsies - Do They Progress?
Epilepsy
Primary: Functional Connectivity